For Couples in "Fertility Limbo," a Real-World Study Published by JARG Finds "Normal" Semen Analysis May Not Tell the Whole Story

A peer-reviewed, multi-clinic study published in the Journal of Assisted Reproduction and Genetics suggests an epigenetic ...
UroToday

EAU 2026: Final Analysis of the Phase 1 First-in-Human Study of an Erdafitinib Intravesical Drug-Releasing System in Patients with NMIBC Harboring Select FGFR A…

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
Ars Technica

Controversial fluoride analysis published after years of failed reviews

Federal toxicology researchers on Monday finally published a long-controversial analysis that claims to find a link between high levels of fluoride exposure and slightly lower IQs in children living ...
ascopubs.org

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Median (range) 6.2 (2.3-15.0) 4.5 (2.0-13.7) 4.3 (0.2-14.1) NOTE. Data are No. (%) unless indicated otherwise. The intention-to-treat analysis set included all patients who underwent random assignment ...
BMJ

Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among adults: an overview of meta-analyses representing over 20.9 million observations ...

Objective To examine and summarise evidence from meta-analyses of cohort studies that evaluated the predictive associations between baseline cardiorespiratory fitness (CRF) and health outcomes among ...
ascopubs.org

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless ...

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial Patients with ...
CNN

What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection

New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the ...